The FDA granted fast track designation to PSV359 for locally advanced unresectable or metastatic FAP-positive solitary fibrous tumors.
Related to this article
UTRxMYCN M1-14 received orphan drug status for soft tissue sarcoma and rare pediatric disease designation for rhabdomyosarcoma.
FDA Approves Denosumab Biosimilar for Skeletal-Related Events, GCTB, and Hypercalcemia of Malignancy
Denosumab-adet (Degevma) is FDA-approved as an Xgeva biosimilar for SRE prevention in myeloma and bone metastases, giant cell tumor of bone, and hypercalcemia of malignancy.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Immunotherapy Regimen Studied by Mayo Clinic for Stage 3 Colon Cancer
2
Dr Berdeja on the Potential Role of CELMoDs in Multiple Myeloma Management
3
Dr Goetz on the Navigation of Oral SERDs and Targeted Therapy in Advanced Breast Cancer
4
The Next Wave: ADCs, Targeted Therapies, and Emerging Strategies in Ovarian Cancer
5